Kangmei Pharmaceutical Co., Ltd.

Kangmei Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company headquartered in Guangdong, with operations historically associated with Puning and Shenzhen. Founded in 1997 by entrepreneur Ma Xingtian, the company developed from a regional pharmaceutical business into a large producer and distributor of traditional Chinese medicine, proprietary medicines, chemical drugs, pharmaceutical ingredients, health foods, and medical equipment. Its business has also included property-management activities. Traditional Chinese medicine has been central to Kangmei’s identity and commercial scope. Its product portfolio has included medicinal herbs and ingredients such as American ginseng, angelica, honeysuckle, notoginseng, radix codonopsis, and salvia, as well as finished medicines and chemical products including clarithromycin, doxazosin mesylate, paracetamol and pseudoephedrine hydrochloride, and propiverine hydrochloride. Products associated with the company have included Ganmaoling Granule, a traditional medicine marketed for cold and influenza symptoms, and Qingkailing Capsules, a traditional medicine and dietary-health product positioned around immune support. The company has also pursued oncology-related products for conditions including lung and breast cancer. Kangmei began a demutualization process in 2000 and completed an initial public offering on the Shanghai Stock Exchange in March 2001 under ticker 600518. Over time, it built a predominantly domestic distribution network, reportedly extending across China through more than 30 branches and a workforce exceeding 10,000 people. Its scale and focus on traditional Chinese medicine made it a significant participant in China’s pharmaceutical sector, although its business remained primarily oriented toward the Chinese market rather than global consumer-brand recognition. The company’s reputation changed sharply after disclosures concerning its financial reporting. In late 2018, Kangmei announced that it was under investigation for possible disclosure violations. In April 2019, it acknowledged that previously reported cash holdings and operating figures were materially misstated. The China Securities Regulatory Commission later concluded that the company had falsified information in several financial reports, including substantial overstatements of revenue, profit, and monetary funds. The disclosures triggered sharp volatility in its Shanghai-listed shares, risk-alert treatment, regulatory penalties, litigation, and the removal of Kangmei from MSCI’s emerging-markets index. The consequences extended beyond the company. In 2020, the company’s controlling shareholder and founder Ma Xingtian was detained in connection with the case, and the securities regulator also imposed restrictions on GF Securities, the sponsor of Kangmei’s listing, citing its role in the matter. In 2021, Ma received a prison sentence and fine. A representative investor-protection body brought a class-action-style case on behalf of investors, while a court later ordered Kangmei to compensate investors and assigned limited joint liability to several independent directors. Kangmei also faced creditor pressure and a bankruptcy petition during the period of financial distress. Kangmei therefore combines two contrasting aspects in its corporate history: the expansion of a large domestic traditional-Chinese-medicine platform and a major governance and financial-reporting failure that prompted regulatory, judicial, and market responses. Detailed current information about its ownership, executive leadership, and post-restructuring operations is not established by the supplied reference material.

Kangmei Pharmaceutical was established in 1997 in Puning, Guangdong, by entrepreneur Ma Xingtian. It developed within China’s expanding pharmaceutical and traditional-Chinese-medicine sector, eventually combining the manufacture and distribution of medicines with activities involving medicinal ingredients, health foods, medical equipment, and property management. The company began a demutualization process in 2000 and listed on the Shanghai Stock Exchange in March 2001 under ticker 600518. Its growth strategy centered on building a large domestic network for traditional Chinese medicine and related products. The company’s reported distribution footprint extended throughout China, with more than 30 branches and a workforce reported at over 10,000 employees. Its portfolio included decoction pieces, proprietary Chinese medicines, chemical drugs, medicinal herbs, dietary supplements, and equipment for medical use. It also pursued medicines associated with cancer treatment, including products for lung and breast cancer. Kangmei’s corporate history was fundamentally altered by its financial-reporting scandal. In late 2018, it disclosed that regulators were investigating possible disclosure violations. The company initially characterized discrepancies in its accounts as accounting errors, but subsequent announcements acknowledged that falsified documents had been involved. In April 2019, it reported that its 2017 annual report had overstated cash holdings by tens of billions of yuan and that its reported operating revenue required a major downward revision. The revelations caused severe share-price volatility, risk-alert treatment on the exchange, and continuing scrutiny from investors and regulators. The CSRC’s investigation concluded in 2019 that Kangmei had deliberately and maliciously misled investors through false financial statements. The regulator imposed penalties on the company and 22 individuals and banned several parties from the securities market. The case was widely viewed as an important test of China’s listed-company disclosure regime and raised concerns among international investors because Kangmei had been included in MSCI’s emerging-markets index. MSCI subsequently removed the company from the index. During the same period, Kangmei experienced severe liquidity and bond pressure, with reports describing government-associated assistance in Guangzhou. Legal and regulatory consequences continued after the initial disclosures. In 2020, founder and actual controller Ma Xingtian was detained, while GF Securities, the sponsor of Kangmei’s initial public offering, was temporarily restricted by the CSRC because of its role in the matter. A representative investor-protection organization filed a case for more than 50 investors in April 2021. A creditor also sought bankruptcy proceedings that year. In November 2021, Ma was sentenced to 12 years in prison and fined 1.2 million yuan. The Guangzhou Intermediate People’s Court later ordered Kangmei to compensate investors for approximately 2.459 billion yuan and required five independent directors to bear 5% to 10% joint liability. The judgment contributed to wider concern among Chinese listed companies about the personal exposure of independent directors. The available reference material does not establish a complete account of Kangmei’s current ownership, executive team, restructuring arrangements, or present product performance. Its documented historical identity is that of a major Chinese traditional-Chinese-medicine company whose expansion was followed by a severe accounting, governance, and investor-compensation crisis.

1. 2021Investor litigation and criminal judgment

   Investor litigation proceeded, Ma Xingtian received a prison sentence, and a court ordered Kangmei to compensate investors while assigning limited joint liability to five independent directors.

   Source
2. 2020Founder detained

   Ma Xingtian was detained in connection with the financial-fraud case.

   Source
3. 2019Financial-reporting scandal becomes public

   Kangmei acknowledged major misstatements in reported cash, revenue, and other financial information, leading to market disruption and regulatory action.

   Source
4. 2019CSRC penalties and market sanctions

   The CSRC concluded that Kangmei had falsified financial reports and penalized the company and associated individuals. MSCI later removed Kangmei from its emerging-markets index.

   Source
5. 2018Investigation into disclosure violations announced

   The company disclosed that it was under investigation over possible violations involving information disclosure.

   Source
6. 2001Shanghai Stock Exchange listing

   Kangmei completed its initial public offering on the Shanghai Stock Exchange under ticker 600518.

   Source
7. 2000Demutualization process begins

   Kangmei began the process of converting its ownership and corporate structure ahead of its public listing.

   Source
8. 1997Company founded in Puning

   Ma Xingtian founded Kangmei Pharmaceutical in Puning, Guangdong.

   Source

A large domestic Chinese pharmaceutical company with a strong traditional-Chinese-medicine orientation.

• Traditional Chinese medicine decoction piecesTraditional Chinese medicine

  Decoction pieces and prepared medicinal materials form the core of Kangmei’s traditional-Chinese-medicine business. The category includes processed herbs and ingredients supplied through the company’s domestic manufacturing and distribution network. The reference material identifies this line as one of the company’s principal activities, but does not provide a complete product catalogue or current sales data.

• Medicinal herbs and ingredientsPharmaceutical ingredients

  Kangmei has manufactured or distributed medicinal materials including American ginseng, angelica, honeysuckle, notoginseng, radix codonopsis, and salvia. These materials support traditional Chinese medicine preparations and related pharmaceutical applications. The available material does not specify whether every named item remains in the current portfolio.

• Ganmaoling GranuleProprietary traditional Chinese medicine

  Ganmaoling Granule is identified as a popular Kangmei-associated traditional Chinese medicine product marketed for cold and influenza symptoms. The reference material states that the product had been in production for more than 30 years, but does not establish its original launch date or current commercial status.

• Qingkailing CapsulesTraditional medicine and dietary-health product

  Qingkailing Capsules are described in the reference material as a Kangmei-associated health-oriented product positioned around immune support. No detailed formulation, regulatory classification, launch date, or current availability is established by the supplied sources.

• Chemical drug portfolioChemical pharmaceuticals

  The company’s chemical-drug portfolio has included clarithromycin, doxazosin mesylate, paracetamol and pseudoephedrine hydrochloride, and propiverine hydrochloride. These products complement Kangmei’s traditional-Chinese-medicine activities, although the supplied material does not provide product-by-product launch dates or current regulatory status.

• Oncology medicinesSpecialty pharmaceuticals

  Kangmei has identified cancer treatment as an important development direction and has brought products to market associated with lung cancer, breast cancer, and other tumors. The reference material does not identify the individual products, indications, or present status in sufficient detail.

• Medical equipmentMedical devices

  Medical equipment is part of Kangmei’s stated manufacturing and distribution scope. The available sources do not identify particular device families, brands, or current market availability.

• Health foods and dietary supplementsHealth and wellness

  Kangmei has operated in health foods and dietary supplements alongside its pharmaceutical and traditional-medicine activities. Qingkailing Capsules are cited as an example of a health-oriented offering, but the available material does not establish the complete range or current status.

• 2019Correction of previously reported financial informationOther

  Regulatory scrutiny identified inconsistencies between Kangmei’s reported cash holdings and the limited interest income generated by those holdings.

  What changed. Kangmei disclosed that its 2017 annual report had materially overstated cash and that reported operating revenue and other figures required revision.

  Aftermath. The disclosures caused sharp share-price declines, risk-alert treatment, further investigation, regulatory penalties, and the removal of Kangmei from MSCI’s emerging-markets index.

  Restated financial figures. The CSRC later determined that reported revenue had been overstated by approximately 29 billion yuan, profits by approximately 4.1 billion yuan, and monetary funds by approximately 88.7 billion yuan. (Financial reports covering 2016–2019, with the initial public disclosure focused on the 2017 annual report)

  Source
• 2019Regulatory and market response to the accounting scandalOther

  The CSRC concluded that Kangmei had engaged in premeditated and malicious deception of investors through false financial reporting.

  What changed. Regulators imposed administrative penalties on Kangmei and 22 individuals, while several parties were barred from the securities market. The exchange placed the shares under special treatment, and MSCI removed Kangmei from its emerging-markets index.

  Aftermath. The case generated prolonged litigation, criminal proceedings, creditor pressure, and debate about Chinese listed-company oversight and the risks faced by international index investors.

  Source
• 2001Public listing on the Shanghai Stock ExchangeStrategy

  After beginning demutualization in 2000, Kangmei pursued access to public capital and a broader corporate platform.

  What changed. The company completed an initial public offering and began trading under ticker 600518.

  Aftermath. The listing supported Kangmei’s development as a large publicly traded Chinese pharmaceutical company, but also subjected it to listed-company disclosure and governance obligations.

  Source

• 2019Kangmei financial-reporting fraudControversy

  Kangmei admitted that earlier financial reports contained major false statements, including inflated cash holdings, revenue, and profits. The CSRC later characterized the conduct as deliberate and imposed penalties on the company and individuals. The scandal led to trading restrictions, index removal, investor litigation, criminal proceedings, and substantial compensation claims.

  Source

1. Kangmei Pharmaceutical
2. Kangmei Pharmaceutical official website